Search
Stewart Washer says Zelda Therapeutics is catching up with market use, given the nature of cannabis regulation. Photo: Attila Csaszar

Zelda in cannabis autism trial

Clinical trials company Zelda Therapeutics aims to pave the way for the use of medicinal cannabis to treat a range of disorders.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Powered by Morningstar ®

Top 10 Shareholders

Substantial shareholders as published in the annual report.
Powered by Morningstar ®

Total Shareholder Return as at 31/01/20

1 year TSR5 year TSR
thOpenDNA
304thZelira Therapeutics13%45%
632ndPeppermint Innovation-35%4%
733rdAusCann Group Holdings-54%51%
790thIntiger Group-67%-20%
677 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Share Transactions

02/01/20
$0 Issued
02/01/20
$903k Issued
02/01/20
$903k Issued
Total value as at the date of the transaction
Powered by Morningstar ®

Revenue

146th↑Zelira Therapeutics$769k
148th↑Peppermint Innovation$710k
149th↑OpenDNA$706k
151st↑AusCann Group Holdings$671k
152nd↑Intiger Group$572k
200 listed industrial companies ranked by revenue.
Powered by Morningstar ®